Indoco Remedies · NSE: INDOCO · BSE: 532612
Q1 FY27 results · Apr–Jun 2026
Indoco Remedies reported revenue from operations of ₹467.50 crore (up 6.8% from Q1 FY26) and net profit of ₹65.44 crore for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 467.50 | 437.89 | +6.8% | 475.61 | −1.7% |
| Other income | 2.18 | 1.63 | +33.7% | (0.04) | Turned profit |
| Total income | 469.68 | 439.52 | +6.9% | 475.57 | −1.2% |
| Profit before tax | 77.72 | (36.66) | Turned profit | (25.00) | Turned profit |
| Net profit for the period | 65.44 | (36.35) | Turned profit | (23.68) | Turned profit |
| Attributable to shareholders of the company | 64.99 | (35.79) | Turned profit | (21.64) | Turned profit |
| EPS, basic (₹) | 7.09 | (3.94) | Turned profit | (2.57) | Turned profit |
| Net margin (%) | 14.0 | -8.3 | -5.0 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 408.97 | 392.53 | +4.2% | 449.13 | −8.9% |
| Other income | 4.47 | 5.58 | −19.9% | 10.35 | −56.8% |
| Total income | 413.44 | 398.11 | +3.9% | 459.48 | −10.0% |
| Profit before tax | 93.22 | (28.40) | Turned profit | 27.62 | +237.5% |
| Net profit for the period | 82.32 | (28.06) | Turned profit | 27.35 | +201.0% |
| EPS, basic (₹) | 8.92 | (3.04) | Turned profit | 2.96 | +201.4% |
| Net margin (%) | 20.1 | -7.1 | 6.1 |
Consolidated
- Filed with BSE
- 28 Jul 2026, 13:05 IST
- Board meeting
- 28 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Jul 2026, 13:05 IST
- Board meeting
- 28 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE